07.03.08
Patheon has entered a sales and marketing agreement with Italy's BSP Pharmaceuticals, a developer and manufacturer of cytotoxic pharmaceutical products. Patheon will promote BSP's cytotoxic manufacturing capacity and development services and Aldo Braca, president, Patheon Europe, will serve as president and chief executive officer of BSP Pharmaceuticals until a successor is named. For a transitional period, Mr. Braca will fill both roles.
"Cytotoxic manufacturing represents a major market opportunity, and a capability that Patheon does not have in its network. With these agreements in place, Patheon can now offer its clients a complete suite of services — which now includes cytotoxics — in contract manufacturing and formulation development," said Wes Wheeler, chief executive officer and president.
Cytotoxic products play a significant role in the oncology market, which is estimated to be approximately $9.6 billion and is expected to reach $12.8 billion by 2009.
"Cytotoxic manufacturing represents a major market opportunity, and a capability that Patheon does not have in its network. With these agreements in place, Patheon can now offer its clients a complete suite of services — which now includes cytotoxics — in contract manufacturing and formulation development," said Wes Wheeler, chief executive officer and president.
Cytotoxic products play a significant role in the oncology market, which is estimated to be approximately $9.6 billion and is expected to reach $12.8 billion by 2009.